Celldex Therapeutics Change In Working Capital Over Time
| CLDX Stock | USD 27.02 0.80 3.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Celldex Therapeutics Performance and Celldex Therapeutics Correlation. Celldex |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.58) | Revenue Per Share 0.164 | Quarterly Revenue Growth 1.103 | Return On Assets (0.20) | Return On Equity (0.30) |
The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change In Working Capital Analysis
Compare Celldex Therapeutics and related stocks such as Ideaya Biosciences, AnaptysBio, and MeiraGTx Holdings PLC Change In Working Capital Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDYA | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.7 M | (284 K) | 84.4 M | (17.8 M) | (41.6 M) | (13.2 M) | (12.5 M) |
| ANAB | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | 9.3 M | (6.5 M) | (7 M) | 4.1 M | 3.5 M | 16.9 M | (6.8 M) | (7.5 M) | 6.8 M | (324 K) | (307.8 K) |
| MGTX | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 8.5 M | (3.9 M) | 57.8 M | (32.6 M) | 31.3 M | 9.6 M | (983 K) | (933.9 K) |
| KROS | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | (6.7 M) | 2.3 M | (16.1 M) | 14.3 M | (2.6 M) | (2.5 M) |
| RNA | 671 K | 671 K | 671 K | 671 K | 671 K | 671 K | 671 K | 671 K | 671 K | 19.1 M | 2.3 M | 5.3 M | 9.8 M | 61.1 M | 64.2 M |
| RVMD | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 38.1 M | (8.8 M) | (8.3 M) | 8.7 M | (13.5 M) | 36.8 M | 38.6 M |
| DAWN | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | (357 K) | 2.7 M | 6.6 M | 9.4 M | 9.9 M |
| SWTX | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 4.9 M | 1.3 M | 5.1 M | 38.1 M | (583 K) | (553.9 K) |
| CYTK | (1.9 M) | (2.3 M) | 2.6 M | 22 M | (34 M) | 37.2 M | 12.1 M | 487 K | (22.9 M) | (336 K) | 89.1 M | 8.5 M | (24.7 M) | 3.1 M | 4.1 M |
| EWTX | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 334 K | 1.9 M | 4.6 M | 4.1 M | (1.6 M) | (1.5 M) |
| DYN | 522 M | (166 M) | 183 M | 268 M | 1 B | (860 M) | 938 M | (1.6 B) | 601 K | 1.4 M | 5.1 M | 9.3 M | (5.4 M) | 26.3 M | 17.4 M |
| CRNX | 189 K | 189 K | 189 K | 189 K | 189 K | 189 K | 189 K | (721 K) | 5.3 M | (2.1 M) | 376 K | 1.1 M | 18.6 M | 8 M | 4.2 M |
| ALXO | (159 K) | (159 K) | (159 K) | (159 K) | (159 K) | (159 K) | (159 K) | (159 K) | (159 K) | 4.3 M | 247 K | (4 M) | 9.8 M | 8.3 M | 8.7 M |
| IMTX | 49.2 M | 49.2 M | 49.2 M | 49.2 M | 49.2 M | 49.2 M | 49.2 M | 49.2 M | 49.2 M | 96.9 M | (25.3 M) | (31.7 M) | 37.3 M | 81.6 M | 85.7 M |
| BCAB | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | 25.1 M | (2.5 M) | 7.4 M | 287 K | 4.7 M | 4.6 M |
| AVTE | 549 K | 549 K | 549 K | 549 K | 549 K | 549 K | 549 K | 549 K | 549 K | 549 K | 974 K | (6.5 M) | 7.8 M | 9.8 M | 10.3 M |
| TVTX | (19.5 K) | 2 K | 3.1 M | 1.5 M | 12.3 M | (11.4 M) | 5.5 M | 3.8 M | 11.1 M | 2.7 M | (26 M) | 80 M | 904 K | (25.5 M) | (24.2 M) |
| VTYX | 591 K | 591 K | 591 K | 591 K | 591 K | 591 K | 591 K | 591 K | 591 K | 591 K | 812 K | 4 M | (5.2 M) | 5.8 M | 6.1 M |
| COGT | 23.9 M | 23.9 M | 23.9 M | 23.9 M | 23.9 M | 23.9 M | (2.3 M) | (2.9 M) | (2.2 M) | (14.1 M) | (5.3 M) | 2 M | 751 K | 11.4 M | 12 M |
Celldex Therapeutics and related stocks such as Ideaya Biosciences, AnaptysBio, and MeiraGTx Holdings PLC Change In Working Capital description
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.My Equities
My Current Equities and Potential Positions
| Celldex Therapeutics | CLDX |
| Classification | Cancer Fighters |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 27.02
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.